Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 08/14/26
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026GlobeNewsWire • 07/27/26
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities FraudBusiness Wire • 06/18/26
Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)PRNewsWire • 06/16/26
Neumora Stock Plunges 49% After Late-Stage Depression Drug FailureZacks Investment Research • 06/16/26
NMRA INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Neumora Therapeutics, Inc.GlobeNewsWire • 06/15/26
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline UpdateGlobeNewsWire • 06/15/26
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare ConferenceGlobeNewsWire • 05/12/26
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 05/07/26
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/06/26
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law FirmGlobeNewsWire • 04/01/26
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 03/30/26
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026GlobeNewsWire • 03/16/26
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewsWire • 02/04/26
Neumora Therapeutics, Inc. (NMRA) Discusses Positive Phase 1b Results for NMRA-511 in Alzheimer's Disease Agitation TranscriptSeeking Alpha • 01/05/26
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming MilestonesGlobeNewsWire • 01/05/26
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease AgitationGlobeNewsWire • 01/05/26
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 11/06/25